Trisalus Life Sciences, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Frankenius Equity AB and Paul Frankenius increased their beneficial ownership in TriSalus Life Sciences, Inc. to 14.0% of common stock through a preferred stock exchange.
NASDAQ
SCHEDULE: TriSalus Life Sciences Insiders Update Significant Ownership Stakes Post-Preferred Stock Exchange
Key insiders Mats Wahlstrom and Kerry R. Hicks, along with HW Investment Partners, updated their beneficial ownership in TriSalus Life Sciences, Inc. following a completed preferred stock exchange offer.
NASDAQ
SCHEDULE 13D/A: Major Shareholder Commits to TriSalus Life Sciences Preferred Stock Exchange and Governance Changes
Frankenius Equity AB, a significant shareholder in TriSalus Life Sciences, Inc., has committed to exchanging its Series A preferred stock for common stock and supporting key corporate governance amendments as part of a new private financing initiative.